Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
HAE:TSX
MONTREAL, April 7, 2008 -- Haemacure Corporation (TSX : HAE), a Montreal-based specialty bio-therapeutics company, will hold its Annual General and Special Meeting of Shareholders on Wednesday, April 9, 2008 at 4 p.m. at The National Club, 303 Bay Street, Toronto, Ontario.
Presentation
Mr. Joseph Galli, Chairman and Chief Executive Officer of Haemacure, will report on accomplishments of 2007 and provide an outlook for 2008 and beyond, including a report on Haemacure's clinical programs for its two proprietary, human product candidates, a fibrin sealant and an active, topical hemostatic agent (thrombin).
Live Webcast
For those who are unable to attend in person, Haemacure will simultaneously host a live webcast of the presentation with slides, at http://events.snwebcastcenter.com/haemacure/20080409/.
About Haemacure
Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant. Follow-on development will focus on surgical hemostats, adhesion prevention, regenerative medecine, drug delivery and combinations with biomaterials. Haemacure has identified eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.
Forward-looking Statements
Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.
